In the treatment arm that included ribavirin
, 25 (100%) achieved an SVR12, compared with 16 (64%) in the arm without ribavirin
. In a separate study, investigators used a 12-week course of ledipasvir-sofosbuvir plus ribavirin for 50 treatment experienced patients with genotype 3 HCV, incluing those with cirrhosis. Overall, SVR12 was
achieved in 82% of the patients, including 89% in those without cirrhosis and 73% in those with cirrhosis.